Clinical trial NCT06999837: [68Ga]Ga-PSMA PET/CT in Hepatocellular Carcinoma: Impact of Multiparametric Dynamic Whole-body Imaging and Kinetic Modeling.
Official title: [68Ga]Ga-PSMA PET/CT in Hepatocellular Carcinoma: Impact of Multiparametric Dynamic Whole-body Imaging and Kinetic Modeling.
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: HCC - Hepatocellular Carcinoma
Keywords: 68Ga-PSMA PET/CT
Hepatocellular carcinoma
multiparametric dynamic whole-body imaging
Lead sponsor: Nantes University Hospital
Sponsor class: OTHER
First posted: 2025-05-31
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The purpose of this study is to evaluate the use of multiparametric dynamic whole-body \[68Ga\]Ga-PSMA PET/CT imaging in newly diagnosed HCC patients or in HCC patients with recent suspicion of refractory, residual, or recurrent disease.


Eligibility criteria: Inclusion Criteria:

1. Provided written informed consent
2. Patient aged ≥ 18 years
3. For cohort A: patient with HCC histologically proven or who meet radiological criteria and are scheduled for biopsy For cohort B: patient with known HCC requiring a new diagnostic imaging workup for suspected refractory, residual or recurrent disease
4. Presence of at least one morphological evaluable lesion according to mRECIST 1.1 using contrast CT/MRI
5. Patient must have an ECOG (Eastern Cooperative Oncology Group) performance status of 0 to 2
6. Patient who are Child-Pugh A
7. Patient must have a life expectancy ≥ 6 months as determined by the study investigator
8. Patient affiliated to or beneficiary of the National Health Service
9. Consent to practice double-barrier contraception after \[68Ga\]Ga-PSMA injection (6 months of contraception for women study participant and their partners, and 3 months for men study participant and their partners)

Exclusion Criteria:

1. Known hypersensitivity to PSMA-11, to any excipient or derivative or to radiographic contrast agents
2. Patient requiring emergent surgery for a ruptured / bleeding HCC
3. Radioembolization within 3 months prior to inclusion
4. Cardiac disease with New York Heart Association classification of III or IV
5. Any major surgery within 4 weeks before enrollment
6. Other known malignancies (except for fully-resected non-melanoma skin cancer or cervical cancer in situ) unless definitively treated and proven no evidence of recurrence for 2 years
7. Any uncontrolled significant medical, psychiatric or surgical condition (active infection (subjects with known human immunodeficiency virus (HIV) positive)), unstable angina pectoris, cardiac arrhythmia, poorly controlled hypertension, poorly controlled diabetes mellitus (glycated haemoglobin (HbA1c) ≥9%), uncontrolled congestive heart disease, etc.) or laboratory findings that, in the opinion of the investigator, might jeopardise the subject's safety or that would limit compliance with the objectives and assessments of the study
8. Woman who are pregnant or breastfeeding. A serum pregnancy test will be performed at the start of the study for all female subjects of childbearing potential
9. Patient under guardianship or trusteeship
10. Patient under judicial protection

Primary outcomes:
measure: Diagnostic performance
timeFrame: 6 months
Secondary outcomes:
measure: Kinetic parameters
timeFrame: Baseline
measure: Diagnostic performance of multiparametric image evaluation approach at the lesion level
timeFrame: 6 months
measure: Diagnostic performance of multiparametric image evaluation approach at the patient level
timeFrame: 6 months
measure: Diagnostic performance of multiparametric image evaluation approach at the patient level
timeFrame: 6 months
measure: Acceptability in terms of comfort
timeFrame: Baseline
measure: Dynamic compared to static imaging
timeFrame: Baseline
Other outcomes:
Locations:
city: Clichy
country: France
facility: HU Paris Nord APHP
city: Nantes
country: France
facility: CHU de Nantes
Study officials:
References: